Danaher's stock plunged despite beating Q2 earnings and revenue estimates, primarily due to a significant reduction in its 2026 core revenue growth forecast and a more cautious outlook for its Bioprocessing business. This guidance cut overshadowed strong current quarter performance and positive commentary on other segments, indicating investor concern over future growth prospects.
Danaher's stock experienced a sharp decline because the company lowered its fiscal 2026 core revenue growth forecast from 3-6% to 3-4% and trimmed its Bioprocessing business growth expectation from high-single-digit to mid-single-digit. This guidance cut, despite beating Q2 earnings and revenue estimates, signals a deceleration in future growth for a key segment, which is a significant concern for investors. While current quarter results were strong and other segments showed resilience, the market is reacting to the long-term outlook, indicating that future growth potential is being re-evaluated. This could lead to continued short-term volatility for DHR, but the long-term impact will depend on whether the company can stabilize or re-accelerate its Bioprocessing segment.